%0 Journal Article
%T Liposomal amphotericin B and leishmaniasis: Dose and response
%A Sundar Shyam
%A Chakravarty Jaya
%J Journal of Global Infectious Diseases
%D 2010
%I Medknow Publications
%X Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
%K Kala-azar
%K Liposomal
%K Amphotericin B
%U http://www.jgid.org/article.asp?issn=0974-777X;year=2010;volume=2;issue=2;spage=159;epage=166;aulast=Sundar